RE:RE:RE:HFS and the CCImportant points on EGRIFTA - it is a way more profitable product for bottom line, so very helpful. And, I wonder how much of the new twice as long average adherance is because of the "Grinspoon NAFLD" effect. Recall he said he uses it for his patients with NAFLD and other metabolic ailments. THTX put in more MSLs to tell the full story for that reason. Perhaps a sign they've gotten a few clinics or doctors to understand that health aspect. It would probably be a much longer course, maybe a lot longer, to keep that under control vs. lipodystrophy. If they can keep that up, will really help profits from here on out. They need that.